The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Neuland Laboratories's 9-Day RSI or its related term are showing as below:
NSE:NEULANDLAB's 9-Day RSI is ranked worse than 96.18% of 1048
companies
in the Drug Manufacturers industry
Industry Median: 51.745
vs NSE:NEULANDLAB: 79.95
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Neuland Laboratories 9-Day RSI Related Terms
NSE:NEULANDLAB vs ZTS, UTHR: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a 9-Day RSI of 79.95 as of Jul. 04, 2026. According to the industry distribution chart, Neuland Laboratories ranks #1008 out of 1048 companies in the Drug Manufacturers industry, placing it in the top 96.2%.
Is Neuland Laboratories' 9-Day RSI too high?
Neuland Laboratories' current 9-Day RSI is 79.95. The Drug Manufacturers industry median 9-Day RSI is 51.75. Neuland Laboratories' value of 79.95 is 54.5% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #1008 out of 1048 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #1008 out of 1048 companies for 9-Day RSI. This places Neuland Laboratories in the lower half of its industry. The industry median 9-Day RSI is 51.75. Neuland Laboratories' value of 79.95 is 54.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 51.75, based on 1,048 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current 9-Day RSI of 79.95 is 54.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 51.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current 9-Day RSI is 79.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,523.60, compared to a current price of ₹18,944.00 — trading 14.6% above its estimated fair value. The current 9-Day RSI is 79.95 and 54.5% above the Drug Manufacturers industry median of 51.75. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current 9-Day RSI is 79.95 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹18,944.00 is trading 14.6% above its estimated GF Value™ of ₹16,523.60.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
9-Day RSI: 79.95
GF Value™: ₹16,523.60 vs. price of ₹18,944.00 (14.6% above fair value)
Industry Position: 54.5% above the Drug Manufacturers median (#1008 of 1048)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 